ALKEM.NSE

Alkem Laboratories Limited

… demand for weight-loss drugs . The patent expiry of semaglutide … active ingredient in blockbuster drugs like Ozempic and Wegovy … to tap the opportunity. Sun Pharmaceutical Industries has launched … 4,200 a month. Glenmark Pharmaceuticals is offering " …

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

Alkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is available under brand names like Semasize and Obesema. The injection is administered once weekly. Alkem offers a pre-filled pen for a month's dosage at Rs 1,800. This makes the weekly cost Rs 450.

In this briefing: Cadrenal Therapeutics Inc - In December 2025 Actinogen Medical — XanaMIA passes interim analysis and marches on Alkem Laboratories: Occlutech M&A to Support Medtech Aspiration. Maintain ADD Hybridan Small Cap Feast: 12 February 2026 Vieworks (100120 KQ/Buy)Steady Performance, Attractive Valuation 1. Cadrenal Therapeutics Inc - In December 2025 In December 2025, Cadrenal Therapeutics, Inc. (CVKD) announced it had acquired VLX-1005, a first-in-class, selective 12-lipoxygenase (12-LOX) inhibitor that is being developed for heparin-induced thrombocytopenia (HIT), a rare, immune-mediated thrombotic disorder with high morbidity and mortality. VLX-1005 is designed to address the underlying platelet-driven inflammatory and prothrombotic mechanisms of HIT rather than coagulation alone. The compound has completed Phase 1 clinical development with a favorable safety and pharmacokinetic profile and has generated encouraging Phase 2 proof-of-concept data indicating a potential reduction in thrombotic complications. 2.